RuncheyResearch
Back to Forecasting

ROIV Forecast Markets

Roivant Sciences Ltd.

7
Active Markets
46%
Avg Probability
Price at Value
Apr 22, 2026

Our prediction ensemble suggests price is consistent with fundamentals.

7 markets analyzedConfidence: MEDIUM
Read Full Thesis

All Markets

7 markets

Will the FDA approve brepocitinib for dermatomyositis by 2026-09-30?

Active
79%
Likely Yes
95% agreement
Sep 30, 2026
IG: 0.80

Will brepocitinib's non-infectious uveitis Phase 3 topline be positive by 2027-03-31?

Active
50%
Likely No
96% agreement
Mar 31, 2027
IG: 0.64

Will IMVT-1402 difficult-to-treat RA Ph2b topline be positive by 2027-03-31?

Active
48%
Likely No
93% agreement
Mar 31, 2027
IG: 0.64

Will IMVT-1402 cutaneous lupus Ph2 PoC readout be positive by 2027-03-31?

Active
50%
Likely No
96% agreement
Mar 31, 2027
IG: 0.56

Will mosliciguat Ph2 PH-ILD topline be positive by 2027-03-31?

Active
45%
Likely No
94% agreement
Mar 31, 2027
IG: 0.56

Will the FDA convene an Advisory Committee for brepocitinib DM by 2026-09-15?

Active
25%
Likely No
93% agreement
Sep 15, 2026
IG: 0.48

Will ROIV announce an M&A deal deploying over $500M by 2026-12-31?

Active
25%
Likely No
94% agreement
Dec 31, 2026
IG: 0.48

Resolution Timeline

Sep 15, 2026
Will the FDA convene an Advisory Committee for brepocitinib DM by 2026-09-15?
Prediction: 25%
Sep 30, 2026
Will the FDA approve brepocitinib for dermatomyositis by 2026-09-30?
Prediction: 79%
Dec 31, 2026
Will ROIV announce an M&A deal deploying over $500M by 2026-12-31?
Prediction: 25%
Mar 31, 2027
Will brepocitinib's non-infectious uveitis Phase 3 topline be positive by 2027-03-31?
Prediction: 50%
Mar 31, 2027
Will IMVT-1402 difficult-to-treat RA Ph2b topline be positive by 2027-03-31?
Prediction: 48%
Mar 31, 2027
Will IMVT-1402 cutaneous lupus Ph2 PoC readout be positive by 2027-03-31?
Prediction: 50%
Mar 31, 2027
Will mosliciguat Ph2 PH-ILD topline be positive by 2027-03-31?
Prediction: 45%